NASDAQ: PGNY · Healthcare Plans

Progyny (PGNY) fair value: undervalued or overvalued?

As of 15 Nov 2026, Faircurve's model values Progyny (PGNY) at $34.78 a share. The stock last closed at $37.15, which puts the model's fair value 6.4% below the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Progyny, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$34.78midpoint of 2,000 simulations
Last close$37.15NASDAQ: PGNY
Gap to fair value-6.4%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 15 Nov 2026 held the fair value at $34.78, within 1% of the run of 7 Nov 2026.

What the model makes of itThe price of $37.15 is 6.4% above it: Fairly valued, on a medium evidence grade.

What's nextNext report on 25 Feb 2027. On the model's Quality Momentum list since 9 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give PGNY?

The calibrated range for PGNY over 63 trading days is $27.82 to $41.32. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $22.22 to $53.66. In 47% of the simulations the fair value came out above the price the model ran on.

$13.38$100.35
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $34.78. Dashed line: the last close, $37.15.

Faircurve Insights · 15 Nov 2026

Progyny, Inc. is a benefits management corporation. It provides specialized solutions for fertility and broader family-building initiatives to employers throughout the United States.

Faircurve's model put the fair value of Progyny at $34.78 a share on 15 Nov 2026. This is the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $35.11, so the fair value moved -0.9%. The calibrated range over 63 trading days is $27.82 to $41.32. It is built from the fair value, since there is no live options data for the stock. The range is calibrated weekly against realised prices, using 13,250 past valuations refreshed on 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence as Medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.

Progyny scores 86 out of 100 on the model's overall quality score, a composite of six quality factors measured against comparable companies. Profitability and earnings quality each score 100. Profitability shows ROIC of 27.1% against a peer median of -37.1%. Earnings quality shows FCF / net income of 2.41x. Growth quality scores 48, with trailing revenue growth of 10.4% against a peer median of 29.9%. The model compares Progyny with Molina Healthcare, Inc. (MOH), Centene Corp. (CNC), Humana Inc. (HUM), Cigna Corporation (CI), Elevance Health Inc. (ELV), CVS Health Corp. (CVS) and UnitedHealth Group Incorporated (UNH).

Written from the figures on this page for the 15 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does PGNY report earnings, and how has the stock reacted?

Progyny's next earnings report is scheduled for 25 Feb 2027. Companies can move their dates.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across PGNY's last 8 reports, ignoring direction, was 16.4%.

0%10%20%30%15.2%2.0%27 Feb '2512.5%2.7%7 Aug '25no quote18.5%6 Nov '2524.6%17.1%26 Feb '26no quote26.8%7 May '26no quote10.4%6 Aug '26no quote18.3%4 Nov '26no quote15.7%5 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

How does PGNY score on business quality?

Progyny's overall quality score is 86 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.10027.1%ROIC-37.1%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).1002.41xFCF / net income
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.4810.4%Revenue growth, trailing29.9%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.7416.2%Net buybacks / market value1.7%
Balance sheetNet debt to EBITDA and interest coverage.92-0.68xNet debt / EBITDA
StabilityDownside volatility of the EBITDA margin over the last five years.921.4 ptsEBITDA margin downside volatility, 5y4.8 pts

How does PGNY compare with similar companies?

The companies in healthcare plans closest to Progyny in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
MOH Molina Healthcare, Inc.$233.09$227.64-2.3%Fairly valued
CNC Centene Corp.$74.77$86.49+15.7%Undervalued
HUM Humana Inc.$461.25$411.63-10.8%Fairly valued
CI Cigna Corporation$300.16$384.76+28.2%Undervalued
ELV Elevance Health Inc.$446.28$454.75+1.9%Fairly valued
CVS CVS Health Corp.$88.59$89.93+1.5%Fairly valued
UNH UnitedHealth Group Incorporated$412.02$405.70-1.5%Fairly valued

What the comparable companies' multiples alone would give for PGNY, the peer-implied price, is $25.87 a share on this run. The fair value weighs that against the company's own multiple.

All healthcare plan stocks ranked by gap to fair value

Progyny at a glance

Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States.

Market value
$2.7B
Sector
Healthcare
Industry
Healthcare Plans
Revenue expected, next twelve months
$1.5B
Consensus revenue growth, next fiscal year
+6.8%
Analysts with estimates
6
Beta to the US market
-0.11
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. PGNY was not among them.

How the fair value is worked out: the model prices Progyny on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for PGNY was $35.11. As of 15 Nov 2026 it is $34.78, a change of -0.9%. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Progyny's valuation

Is Progyny stock undervalued or overvalued?

On Faircurve's model, PGNY reads as Fairly valued as of 15 Nov 2026. The model's fair value is $34.78 a share against a last close of $37.15, a gap of -6.4%.

What is PGNY's fair value?

$34.78 a share as of 15 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $22.22 to $53.66.

What price range does the model give PGNY?

$27.82 to $41.32 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.

When does Progyny report earnings next?

The next report is scheduled for 25 Feb 2027. Companies can move their dates.

How much has PGNY moved on past earnings reports?

Across its last 8 reports the median two session move was 16.4%, ignoring direction. The largest was +26.8% around the report of 7 May 2026.

How confident is the model in this valuation?

The model's evidence grade for PGNY is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on PGNY

The model has an idea open on PGNY under Quality Momentum since 9 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on PGNY with their outcomes. A free account is enough.

Keep reading